healthpharma
Novo Nordisk A/S (CPH: NOVO-B) climbed 3.0% to an all-time high on Tuesday after China approved the sale of its weight-loss treatment Wegovy. Year-to-date, shares of the pharmaceutical giant are now up a whopping 45%. Why is it a big deal for Novo Nordisk stock?Novo Nordisk is yet to reveal the details of its launch plan. How much will its weight-loss drug cost in China remains unknown as well. Nonetheless, the announcement is significant for Novo Nordisk stock as it clears the path for Wegovy to generate sales from the world’s second largest economy. Initially, the weekly injectable will be a...
Invezz
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220. Why is it significant for Alnylam Pharmaceuticals stock?Vutrisiran demonstrated significant efficacy in reducing mortality and cardiovascular complications in the aforementioned study. It’s a drug that targets transthyretin amyloidosis with cardiomyopathy – a condition that stiffens the heart and impairs blood pumping. Pushkal Garg – the chief medical offi...
Invezz
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing. Alimera Sciences stock valued at a 75% premiumANI Pharmaceuticals is willing to pay $5.50 in cash for each share of Alimera Sciences. It has also agreed to 50 cents a share of additional payout provided that the acquiree hits certain revenue targets in 2026 and 2027. Nikhil Lalwani – the chief executive of $ANIP said in a press release on Monday: We believ...
Invezz
Altimmune (NASDAQ: ALT) stock price drifted upwards on Monday amid optimism that it will become a leading player in the weight loss industry. It rose by over 2%, meaning that it has soared by over 25% from the lowest point last week. Pemvidutide hopes riseAltimmune is a small biotech company that is aiming to become a major player in the weight loss and nonalcoholic steatohepatitis industries. Pemvidutide, its main drug, has shown encouraging signs in clinical trials, with most of the subjects losing substantial weight. These users lost respectable weight loss in about 48 weeks. Pemvidutide wo...
Invezz
Zealand Pharma (CPH: ZEAL) rallied more than 20% this morning after reporting positive results from an early stage trial of its new weight loss treatment. The biotech firm is now trading at an all-time high. Why is it significant for Zealand Pharma stock?Petrelintide – a long-acting amylin analog of Zealand Pharma showed significant efficacy in a 16-week trial, as per its press release on Friday. Participants receiving high doses successfully lowered their body weight by 8.6% versus only 1.7% observed in the placebo group. Only one participant out of a total of 48 had to withdraw from the stud...
Invezz
Sarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in after-hours trading last night. But why? Ground-breaking medical breakthroughToward the end of the trading day yesterday, Sarepta announced that it had obtained approval from the U.S. Food and Drug Administration (FDA) for a treatment targeting a rare genetic disease called Duchenne muscular dystrophy (DMD). Sarepta’s DMD treatment, named ELEVIDYS (delandistrogene moxeparvovec-rokl), was given full FDA appr...
Invezz
Sarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys. Elevidys is the company’s treatment for Duchenne muscular dystrophy. Why is it significant for Sarepta Therapeutics stock?The FDA granted accelerated approval for a label expansion of “delandistrogene moxeparvovec” to include non-ambulatory patients on Thursday. The decision is significant for individuals with DMD who have lost the ability to walk. Jerry Mendell – the co-inventor of Elevidys said in a press release%2C...
Invezz
Pfizer (NYSE: PFE) stock price has crashed hard in the past few years as demand for Covid-19 vaccines faded globally. It was trading at $28 on Monday, down from the pandemic high of $55.56. It has also underperformed the likes of Eli Lilly, Johnson & Johnson, and Amgen. Pfizer’s history of acquisitionsPfizer’s crash has brought focus on the company’s history of growth through acquisitions. In 2023, the company acquired Seagen in a $43 billion deal, a move that gave it access to cancer treatments. Seagen had over $2 billion in annual revenue in 2023 and has 113 drugs in its pipeline. While Seag...
Invezz
The Mustang Bio stock price closed on a high yesterday, trading at $0.75. The pharmaceutical company has gone vertical in the past 24 hours, climbing 476.9% to go from $0.13 to $0.75 in a single day. But why? Potential cancer breakthroughYesterday, Mustang Bio announced via press release that it had had promising results from clinical trials relating to an experimental treatment developed by Mustang Bio for Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer. The trial, which contained just 10 patients, showed a marked improvement over more traditional existing treatments for the...
Invezz
AstraZeneca, the largest pharmaceutical group in Britain, announced that the U.S. Food and Drug Administration (FDA) has approved its lung cancer drug, Imfinzi, for use alongside other chemotherapy treatments. The approval is specifically for Imfinzi in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy. This regimen is intended for adults suffering from primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). Significant trial resultsThe approval follows a clinical trial that demonstrated Imfinzi’s efficacy in reducing the risk of di...
Invezz
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら